Health Policy Watch: Despite sensational reports, COVID-19 vaccine safety outweighs risks
The overall benefits of COVID-19 vaccines far outweigh potential risks, according to a recent study of 99 million vaccinated people – despite a number of misleading and sensational reports about the study. The study, published in the journal Vaccine in mid-February, aimed to get more precise estimates of the risk of adverse events following vaccination.
Read more here.
Infectious Disease Advisor: COVID-19 mRNA vaccines: Benefits outweigh risks for young children, infants
According to results of a study published in the Journal of the Pediatric Infectious Diseases Society, the benefits of receiving primary series mRNA COVID-19 vaccines outweigh the risks for children and infants aged 6 months to 4 years, regardless of underlying medical conditions or infection-induced immunity.
Read more here.
Health Policy Watch: New research reveals high prevalence of persistent COVID infections
A much higher percentage of the population has experienced “persistent” COVID-19 infections lasting more than 30 days than initially assumed, according to new research by the University of Oxford. The study, published in Nature, found that one to three of every 100 infections may last a month or longer.
Read more here.
Infectious Disease Special Edition: Novel ensitrelvir provides early resolution of many common COVID-19 symptoms
The novel COVID-19 treatment, ensitrelvir, shows both clinical symptom improvement and an antiviral effect in a predominantly vaccinated population regardless of risk factors. Ensitrelvir is a 3CL protease inhibitor; 3CL protease is an enzyme that is essential for the replication of SARS-CoV-2. The FDA granted ensitrelvir a Fast Track designation; it is approved in Japan and Singapore and distributed under the name Xocova.
Read more here and watch a video here.
HealthBioAI announces the acceptance by FDA to proceed with a randomized clinical trial for the treatment of Long COVID/Post-Acute Sequelae of COVID (PASC) with Selzentry® (maraviroc) in combination with Lipitor (atorvastatin)
The clinical trial is a 32-week randomized, 252 patient, double-blind, placebo-controlled, multicenter study that is evaluating the safety and efficacy of maraviroc and atorvastatin for the treatment of patients living with Long COVID/Post-Acute Sequelae of COVID (PASC).
Read more here.
TheBodyPro: Swiss study compares factors affecting COVID-19 susceptibility by HIV status
Susceptibility to SARS-CoV-2, the virus that causes COVID-19, did not differ by HIV serostatus in a Swiss study of individuals who were mostly virally suppressed, but it was lower among smokers compared to non-smokers. Most participants living with HIV were virally suppressed.
Read more here.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.